CARLOS PEREZ: Open Payments
NPI 1033229661 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,201 in 97 payments from 14 companies in 2025. Trend: 2023 $2,085 · 2024 $1,907 · 2025 $2,201
Food & beverage: $2,196Education: $5
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $273 |
| Otsuka America Pharmaceutical, Inc. | 14 | $271 |
| Neurocrine BioSciences, Inc. | 6 | $267 |
| Janssen Pharmaceuticals, Inc | 5 | $239 |
| Teva Pharmaceuticals USA, Inc. | 15 | $211 |
| Alkermes, Inc. | 8 | $186 |
| Vanda Pharmaceuticals Inc. | 10 | $165 |
| ABBVIE INC. | 4 | $80 |
| Lundbeck LLC | 3 | $68 |
Products named: REXULTI, Auvelity, CAPLYTA, INGREZZA, INVEGA SUSTENNA, UZEDY, FANAPT, ARISTADA.
Industry payments across GA — which companies pay providers there.
